Cyclosporin A Reverses Chemoresistance in Patients with Gynecologic Malignancies

Neoplasia

Volumn 1, Issue 2, 1999, Pages 118-122

  Sood, Anil K ^a   Sorosky, Joel I ^a   Squatrito, Robert C ^a   Skilling, Jeffrey S ^a   Anderson, Barrie ^a   Buller, Richard E ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Cyclosporine; Multidrug resistance; Resistance modulation

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; CHORIOCARCINOMA; DISEASE COURSE; FEMALE; FEMALE GENITAL TRACT TUMOR; HUMAN; MIDDLE AGED; MULTIDRUG RESISTANCE; OVARY TUMOR; TIME; TREATMENT OUTCOME; UTERINE CERVIX TUMOR; UTERUS CANCER;

CHORIOCARCINOMA; CYCLOSPORINE; DISEASE PROGRESSION; DRUG RESISTANCE, MULTIPLE; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; OVARIAN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; UTERINE NEOPLASMS;

EID: 0033139966     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900019     Document Type: Article

References (29)

1. Sonneveld P, Durie BGM, Lokhorst HM, Marie J-P, Solbu G, Suciu S, Zittoun R, Lowenberg B, and Nooter K (1992). Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 340, 255-259.
2. Raderer M, and Scheithauer W (1993). Clinical trials of agents that reverse multidrug resistance. A literature review. Cancer 72, 3553-3563.
3. Elliott JF, Lin Y, Mizel SB, Bleackley RC, Harnish DG, and Paetkau V (1984). Induction of interleukin 2 messenger RNA inhibited by cyclosporin A. Science 226, 1439-1441.
4. Lum BL, Kaubisch S, and Yahanda AM (1992). Alteration of etoposide pharmacokinetics, and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10, 1635-1642.
5. Ross DD, Wooten PJ, Sridhara R, Ordonez JV, Lee EJ, and Schiffer CA (1993). Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blase cells from patients with previously untreated acute myeloid leukemia. Blood 82, 1288-1299.
6. Yahanda AM, Adler KM, Fisher GA, Brophy NA, Halsey J, Hardy, Gosland MP, Lum BL, and Sikic BI (1992). Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 10, 1624-1634.
7. Morgan RJ, Margolin K, Raschko J, Akman S, Leong L, Somlo G, Sconlon K, Ahn C, Carroll M, and Doroshow JH (1995). Phase I trial of carboplatin, and infusional cyclosporine in advanced malignancy. J Clin Oncol 13, 2238-2246.
8. Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, and Sikic BI (1994). Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 12, 835-842.
9. Manetta A, Boyle J, Berman ML, DiSaja PJ, Lentz S, Liao SY, Mutch D, and Slater L (1994). Cyclosporin enhancement of cisplatin chemotherapy in patient with refractory gynecologic cancer. Cancer 73, 196-199.
10. Chambers SK, Davis CA, Chambers JT, Schwartz PE, Lorber MI, and Handschumacher RE (1996). Phase I trial of intravenous carboplatin and cyclosporin A in refractory gynecologic cancer patients. Clin Cancer Res 2, 1699-1704.
11. Chambers SK, Davis CA, Schwartz PE, Kohorn EI, and Chambers JT (1996). Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: A phase II study. Clin Cancer Res 2, 1693-1697.
12. Markman M, and Hoskins W (1992). Responses to salvage chemotherapy in ovarian cancer: A critical need for precise definitions of the treated population. J Clin Oncol 4, 513-515.
13. Menzin AW (1996). GOG Common Toxicity Criteria, Appendix 3. In Chemotherapy of Gynecologic Cancers. SC Rubin (Ed). Lippincott-Raven, Philadelphia, PA. pp. 189-196.
14. American Society of Clinical Oncology (1996). Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines. J Clin Oncol 14, 1957-1960.
15. Weinstein RS, Kuszak JR, Kluskens LF, and Coon JS (1990). P-glycoproteins in pathology: The multidrug resistance gene family in humans. Hum Pathol 21, 34-48.
16. Ross HJ, Canada AL, and Slater LM (1997). Cyclosporin A enhances paclitaxel toxicity against leukemia and respiratory epithelial cancers. Clin Cancer Res 3, 57-62.
17. Twentyman PR (1988). Modification of cytotoxic drug resistance by non-immuno-suppressive cyclosporins. Br J Cancer 57, 254-8.
18. Scanlon KJ, Kashani-Sabet M, Miyachi H, Sowers LC, and Rossi J (1989). Molecular basis of cisplatin resistance in human carcinomas: Model systems and patients. Anticancer Res 9, 1301-1312.
19. Stratton JA, and DiSaia PJ (1988). Reversal of cisplatinum resistance by cyclosporin A in xenografts of fresh human ovarian carcinoma. Proc Am Assoc Cancer Res 29, 479.
20. Kashani-Sabet M, Wang W, and Scanlon KJ (1990). Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells. J Biol Chem 265, 11285-11288.
21. Holm PS, Scanlon KJ, and Dietel M (1994). Reversion of multidrug resistance in the p-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme. Br J Cancer 70, 239-43.
22. Rodenbrug CJ, Nooter K, Herweijer H, Seynaeve C, Oosterom R, Stoter G, and Verweij J (1991). Phase II study of combining vinblastine and cyclosporin A to circumvent multidrug resistance in renal cell cancer. Ann Oncol 2, 305-6.
23. Verweij J, Herweijer H, Planting A, Rodenburg CJ, Boersma A, Stoter G, and Nooter K. In vitro and in vivo studies on the effect of cyclosporin A in the circumvention of multidrug resistance. Proc Am Soc Clin Oncol 9, 74.
24. List AF, Spier C, Greer J, Azar C, Hutter J, Wolff S, Salmon S, Futscher B, and Dalton W (1992). Biochemical modulation of anthracycline resistance(MDR) in acute leukemia with cyclosporin A (CSA). Proc Am Soc Clin Oncol 11, 264.
25. Manetta A, Blessing JA, and Hurteau JA (1998). Evaluation of cisplatin, and cyclosporin A in recurrent platinum-resistant ovarian cancer: A phase II study of the Gynecologic Oncology Group. Gynecol Oncol 68, 45-46.
26. Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, Shimbo T, and Suthanthiran M (1999). Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999, 397, 530-534.
27. Twentyman PR, and Bleehen NM (1991). Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin. Eur J Cancer 27, 1639-1642.
28. Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, and Loor F (1991). In vivo circumvention of p-glycoprotein mediated multidrug resistance of tumor cells with SDZ PSC-833. Cancer Res 51, 4226-4233
29. Boesch D, and Loor F (1994). Extent and persistence of P-glycoprotein inhibition in multidrug-resistant P388 cells after exposure to resistance-modifying agents. Anticancer Drugs 5, 229-238.